HALLE (SAALE), Germany, 12 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced updates […]
License and supply agreement is based on Crossbeta’s proprietary technology and supports Probiodrug’s biomarker development activities HALLE (SAALE), Germany, UTRECHT, The Netherlands, 30 June 2016 […]
Patent grants cover Probiodrug’s lead QC inhibitor PQ912, for treatment of AD and the use of QC inhibition for treatment of mild cognitive impairment (MCI) Strengthens […]
HALLE (SAALE), Germany, 27 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that the […]
HALLE (SAALE), Germany, 20 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that its […]
HALLE/SAALE, Germany, 12 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces its […]
Probiodrug to Present at the 1st Meeting of The Society for CSF analysis and Clinical Neurochemistry
HALLE/SAALE, Germany, 11 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces today that two […]
HALLE/SAALE, Germany, 4 May 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its first […]
HALLE/SAALE, Germany, 3 May 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is […]